EyePoint Pharma Files DEF 14A for Executive Compensation
Ticker: EYPT · Form: DEF 14A · Filed: Apr 28, 2025 · CIK: 1314102
| Field | Detail |
|---|---|
| Company | Eyepoint Pharmaceuticals, Inc. (EYPT) |
| Form Type | DEF 14A |
| Filed Date | Apr 28, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
Related Tickers: EYPT
TL;DR
EYPT DEF 14A out - exec comp details for Duker, Lurker, etc. for 2022-2024.
AI Summary
EyePoint Pharmaceuticals, Inc. filed a DEF 14A on April 28, 2025, for the period ending June 18, 2025. The filing details executive compensation and other corporate governance matters. Key individuals mentioned include Jay Duker and Nancy Lurker, with compensation data spanning fiscal years 2022, 2023, and 2024.
Why It Matters
This filing provides transparency into how EyePoint Pharmaceuticals compensates its top executives, which can influence investor decisions and employee morale.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine but can reveal significant information about executive compensation and corporate governance that may impact stock price.
Key Numbers
- 2022 — Fiscal Year (Compensation data reported for this year.)
- 2023 — Fiscal Year (Compensation data reported for this year.)
- 2024 — Fiscal Year (Compensation data reported for this year.)
Key Players & Entities
- EyePoint Pharmaceuticals, Inc. (company) — Filer
- Jay Duker (person) — Executive
- Nancy Lurker (person) — Executive
- pSivida Corp. (company) — Former Company Name
- pSivida LTD (company) — Former Company Name
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose of this DEF 14A filing is to provide information regarding the solicitation of proxies for the company's annual meeting of stockholders, including details on executive compensation, director nominations, and other corporate governance matters.
Who are the key individuals whose compensation is detailed in this filing?
Key individuals whose compensation is detailed include Jay Duker and Nancy Lurker, among other executive officers and directors.
What fiscal years are covered by the compensation data in this filing?
The compensation data reported in this filing covers the fiscal years 2022, 2023, and 2024.
When was this DEF 14A filing submitted?
This DEF 14A filing was submitted on April 28, 2025.
What was EyePoint Pharmaceuticals, Inc. formerly known as?
EyePoint Pharmaceuticals, Inc. was formerly known as pSivida Corp. and prior to that, pSivida LTD.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 28, 2025 by Jay Duker regarding EyePoint Pharmaceuticals, Inc. (EYPT).